EVENTS | VIEW CALENDAR
AIBioTech partners with AutoGenomics to expand molecular testing
RICHMOND, Va.— American International Biotechnology Services (AIBioTech) has taken the wraps off a partnership with AutoGenomics in which they will utilize the automated Infiniti analyzer and multiple applications that they have validated.
Financial terms of the agreement were not released.
According to William Miller, CEO of AIBioTech, the automation provided by AutoGenomics' Infiniti Analyzer has enhanced workflow in his company's laboratories.
"With their expanding menu of molecular applications we have found AutoGenomics to be very responsive in meeting our emerging testing needs," he adds.
Fareed Kureshy, CEO of AutoGenomics, says his company has been impressed with the test portfolio that is being offered by AIBioTech.
"The versatility of our BioFilmChip Microarray technology allows us to rapidly develop new applications to meet the needs of AIBioTech," Kureshy notes.
Miller also points out that the sensitivity of the instrument "allows us to detect diseases at an early stage."
"This allows our patients to get treatment well before their condition deteriorates," he says. "For example, our HPV genotype can detect a strand with as little as five copies. The current technology calls for 50,000 copies for initial detection."
The partnership has a single focus, as Miller points out, with AIBioTech and AutoGenomics focusing on the patient above all else.
"The partnership will strive towards providing accurate results in a timely manner with special emphasis in eliminating re-collection procedures and on providing rapid turnaround time," he notes.
In addition to the focus of the partnership, there are some specific goals the parties will strive to achieve.
"(We hope) to improve on current technology and to provide the physicians with a more precise, faster and accurate diagnosis that will help them better assess the patient condition and course of treatment," Miller says. "We want the physician to have the best tools and tests available to get the patient the necessary care."
As a result, Miller says the partnership will offer AIBioTech clients the availability to obtain more accurate, sensitive and faster results.
"Along with quick turnaround time, the accuracy of the test will also eliminate the need for retesting or recollection," he adds.
Success of the partnership will ultimately be measured by the amount of assays AIBioTech adopts from the Autogenomics platform.
"As we continue to obtain proof of concept with current assays, the natural progression will be to adopt the technology into additional panels which AIBioTech and Autogenomics can co-develop," concludes Miller.
AIBioTech, a division of Bostwick Laboratories, is a full service, comprehensive contract research organization offering state-of-the-art technology platforms to investigators in pharma, biotech, the government and academic institutions.
AutoGenomics Inc., a privately held company based in Carlsbad, Calif., has developed the first automated, microarray based multiplexing diagnostic platforms that can be used to assess disease signatures with novel genomic and proteomic markers in the area of genetic disorders, infectious disease, cancer and pharmacogenetics.